Evaluation: Novel Therapeutic Approaches to Alzheimer's Disease: A Focus on Immunotherapy
*
*
*
Use the scale: 1=Poor, 2=Fair, 3=Good, 4=Very Good, 5=Excellent
12345
Discuss the importance of early detection and management of AD
Identify immunotherapies in development for the treatment of AD
Analyze the use of biomarkers to identify patients with early-stage AD
*
Please use the scale: 1=Not at all familiar, 2=Somewhat familiar, 3=Familiar, 4=Very familiar, 5=Expert on this subject, 6=N/A for me
123456
The pivotal pathogenic AD pathway involving beta-secretase and gamma- secretase
The ongoing phase III trials of solanezumab, gantenerumab, and aducanumab and the ongoing phase II trials of crenezumab and BAN-2401
That the negative or marginal results from anti-amyloid trials to date may have been caused by wrong disease stage, a heterogeneous population, limited target engagement due to ARIA-related dose restrictions, and/or only a partial effect observed with monotherapy
Potential for combination therapy with secretase inhibitors, anti-amyloid antibodies, anti-tau agents, and neuroprotective drugs
That Alzheimer’s pathology, as defined by the presence of amyloid and tau on PET probably appears approximately 10 years before the illness
That tau PET shows the presence of pathology even in younger individuals and that in normal elderly, between the ages of 65 and 85 years, the presence of tau on PET imaging correlates with worse memory performance
*
Please use the scale: 1=Not at all familiar, 2=Somewhat familiar, 3=Familiar, 4=Very familiar, 5=Expert on this subject, 6=N/A for me
123456
The pivotal pathogenic AD pathway involving beta-secretase and gamma- secretase
The ongoing phase III trials of solanezumab, gantenerumab, and aducanumab and the ongoing phase II trials of crenezumab and BAN-2401
That the negative or marginal results from anti-amyloid trials to date may have been caused by wrong disease stage, a heterogeneous population, limited target engagement due to ARIA-related dose restrictions, and/or only a partial effect observed with monotherapy
Potential for combination therapy with secretase inhibitors, anti-amyloid antibodies, anti-tau agents, and neuroprotective drugs
That Alzheimer’s pathology, as defined by the presence of amyloid and tau on PET probably appears approximately 10 years before the illness
That tau PET shows the presence of pathology even in younger individuals and that in normal elderly, between the ages of 65 and 85 years, the presence of tau on PET imaging correlates with worse memory performance
*
Please use the scale: 1=Never, 2=Not Often, 3=Sometimes, 4=Often, 5=Always, 6=N/A
123456
I stay up-to-date on the advances in biomarkers for the diagnosis of Alzheimer’s disease
I stay up-to-date on the research regarding combination treatment with both existing and emerging medications
*
Please use the scale: 1=Never, 2=Not Often, 3=Sometimes, 4=Often, 5=Always, 6=N/A
123456
I stay up-to-date on the advances in biomarkers for the diagnosis of Alzheimer’s disease
I stay up-to-date on the research regarding combination treatment with both existing and emerging medications
*
Please use the scale: 1=Strongly Disagree, 2=Disagree, 3=Neutral, 4=Agree, 5=Strongly Agree
12345
Overall, the activity met my learning needs
The information presented was without promotional or commercial bias
The information presented was scientifically rigorous and evidence based
The information presented provided appropriate and effective opportunities for active learning (discussion, Q&A)
The information presented promoted improvements or quality in health care
The quality of the educational process was satisfactory and appropriate
The information provided with regard to faculty relations met my needs for disclosure
The speakers were knowledgeable and presented the information clearly
The format of the discussion was relevant and enhanced my knowledge of the subject
The registration process for this meeting was efficient and professional
*
Use the scale: 1=Poor, 2=Fair, 3=Good, 4=Very Good, 5=Excellent
12345
Paul S. Aisen, MD (Program Chair)
Keith Johnson, MD
Stephen Salloway, MD, MS
*
*
*
*

Attestation to time spent on activity

The Elsevier Office of Continuing Medical Education designates this live activity for a maximum of 1.75 AMA PRA Category 1 CreditsTM. I participated in this CME activity and claim ______ credits.

*